Literature DB >> 25224814

Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial.

Sarbani Ghosh-Laskar1, Nikhil Kalyani1, Tejpal Gupta1, Ashwini Budrukkar1, Vedang Murthy1, Manju Sengar2, Devendra Chaukar3, Prathamesh Pai3, Pankaj Chaturvedi3, Anil D'Cruz3, Jaiprakash Agarwal1.   

Abstract

BACKGROUND: The purpose of this study was to report the results of a phase III, 3-arm, randomized trial comparing conventional radiotherapy (RT) to concurrent chemoradiotherapy (CRT) and accelerated RT in advanced head and neck squamous cell carcinoma (HNSCC).
METHODS: One hundred eighty-six of 750 planned patients were randomized to receive one of the following treatment plans: RT (66-70 Gy/2 Gy fraction/5 fractions weekly; CRT of weekly cisplatin (30 mg/m(2) ) with the same RT dose; or accelerated RT alone of 66 to 70 Gy/2 Gy fraction/6 fractions weekly were available for analysis. The primary endpoint was locoregional control at 5 years.
RESULTS: The mean follow-up was 54 months. Among the 3 arms, CRT showed superior locoregional control (49%; p = .049). RT had lower grade ≥3 mucositis and late toxicity.
CONCLUSION: CRT is associated with significantly better locoregional control as compared to RT and accelerated RT with higher but acceptable acute and late toxicities.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  accelerated radiotherapy; chemoradiotherapy (CRT); cisplatin; head and neck squamous cell carcinoma (HNSCC); radiotherapy (RT)

Mesh:

Substances:

Year:  2015        PMID: 25224814     DOI: 10.1002/hed.23865

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  13 in total

1.  [Once-a-week versus once-every-three-weeks cisplatin application in combined chemoradiotherapy for locally advanced head and neck cancer?]

Authors:  Martina Becker-Schiebe; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2018-05       Impact factor: 3.621

Review 2.  Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.

Authors:  Petr Szturz; Kristien Wouters; Naomi Kiyota; Makoto Tahara; Kumar Prabhash; Vanita Noronha; Ana Castro; Lisa Licitra; David Adelstein; Jan B Vermorken
Journal:  Oncologist       Date:  2017-05-22

Review 3.  The Cisplatin Total Dose and Concomitant Radiation in Locoregionally Advanced Head and Neck Cancer: Any Recent Evidence for Dose Efficacy?

Authors:  Lindsay Carlsson; Scott V Bratman; Lillian L Siu; Anna Spreafico
Journal:  Curr Treat Options Oncol       Date:  2017-07

4.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.

Authors:  Benjamin Lacas; Alexandra Carmel; Cécile Landais; Stuart J Wong; Lisa Licitra; Jeffrey S Tobias; Barbara Burtness; Maria Grazia Ghi; Ezra E W Cohen; Cai Grau; Gregory Wolf; Ricardo Hitt; Renzo Corvò; Volker Budach; Shaleen Kumar; Sarbani Ghosh Laskar; Jean-Jacques Mazeron; Lai-Ping Zhong; Werner Dobrowsky; Pirus Ghadjar; Carlo Fallai; Branko Zakotnik; Atul Sharma; René-Jean Bensadoun; Maria Grazia Ruo Redda; Séverine Racadot; George Fountzilas; David Brizel; Paolo Rovea; Athanassios Argiris; Zoltán Takácsi Nagy; Ju-Whei Lee; Catherine Fortpied; Jonathan Harris; Jean Bourhis; Anne Aupérin; Pierre Blanchard; Jean-Pierre Pignon
Journal:  Radiother Oncol       Date:  2021-01-27       Impact factor: 6.280

5.  Any day, split halfway: Flexibility in scheduling high-dose cisplatin-A large retrospective review from a high-volume cancer center.

Authors:  Jung Julie Kang; Vatche Tchekmedyian; Nader Mohammed; Alisa Rybkin; Sarin Kitpanit; Ming Fan; Huili Wang; Stephanie M Lobaugh; Zhigang Zhang; Anna Lee; Linda Chen; Yao Yu; Kaveh Zakeri; Daphna Y Gelblum; Nadeem Riaz; Sean M McBride; C Jillian Tsai; Marc A Cohen; Jennifer R Cracchiolo; Luc G Morris; Bhuvanesh Singh; Snehal Patel; Ian Ganly; Jay O Boyle; Richard J Wong; Juliana Eng; Wanqing Iris Zhi; Kenneth Ng; Alan L Ho; Lara A Dunn; Loren Michel; James V Fetten; David G Pfister; Nancy Y Lee; Eric J Sherman
Journal:  Int J Cancer       Date:  2021-02-27       Impact factor: 7.316

6.  Orbital apex syndrome affecting head and neck cancer patients: A case series.

Authors:  A-C Prado-Ribeiro; A-C Luiz; M-A Montezuma; M-P Mak; A-R Santos-Silva; T-B Brandão
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2017-05-01

7.  Matched pair analysis for comparison of survival outcome of alternative regimens to standard three-weekly cisplatin-based concurrent chemoradiation of head and neck cancer.

Authors:  Hye Ri Han; Sung Jun Ma; Gregory M Hermann; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni A Kuriakose; Michael R Markiewicz; Jon M Chan; Mary E Platek; Andrew D Ray; Fangyi Gu; Wesley L Hicks; Anurag K Singh
Journal:  Ann Transl Med       Date:  2021-05

8.  Chemoradiotherapy with high-dose cisplatin compared with weekly cisplatin for locally advanced head and neck squamous cell carcinoma.

Authors:  Ryan T Hughes; Mercedes Porosnicu; Beverly J Levine; Thomas W Lycan; Rachel F Shenker; Bart A Frizzell; Kathryn M Greven
Journal:  J Med Imaging Radiat Oncol       Date:  2021-07-26       Impact factor: 1.667

Review 9.  The Indian scenario of head and neck oncology - Challenging the dogmas.

Authors:  Vidisha Tuljapurkar; Harsh Dhar; Aseem Mishra; Swagnik Chakraborti; Pankaj Chaturvedi; Prathamesh S Pai
Journal:  South Asian J Cancer       Date:  2016 Jul-Sep

Review 10.  Radiotherapy for laryngeal cancer-technical aspects and alternate fractionation.

Authors:  Hideya Yamazaki; Gen Suzuki; Satoaki Nakamura; Ken Yoshida; Koji Konishi; Teruki Teshima; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2017-07-01       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.